دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Sodium–glucose cotransporter 2 inhibitors, weight loss therapies, and ferric carboxymaltose: new light shed on innovative ways to reduce cardiovascular risk
Filippo Crea
doi : 10.1093/eurheartj/ehad815
Volume 44, Issue 48, 21 December 2023
Heart failure in Africa: challenges of dealing with a heterogeneous syndrome in a heterogeneous continent
Neusa Jessen 1,2, Ana Olga Mocumbi 1,3, and Karen Sliwa
Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering
Giuseppe Danilo Norata 1 and Lale Tokg?zo?lu
Future research with advanced imaging technology and biomarkers
Fabrizio Montecucco 1,2 and Thomas H. Schindler
Five easy pieces only account for a fraction of incident cardiovascular disease and all-cause deaths
Giovanna Liuzzo 1,2* and Carlo Patrono
Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors
Milton Packer
The cardiovascular effects of novel weight loss therapies
Muhammad Shariq Usman1,2, Melanie Davies3,4, Michael E. Hall5, Subodh Verma6, Stefan D. Anker7,8, Julio Rosenstock 9, and Javed Butler
Prevalence and incidence of diastolic dysfunction in atrial fibrillation: clinical implications
Jwan A. Naser 1, Eunjung Lee1, Christopher G. Scott 2, Austin M. Kennedy 2, Patricia A. Pellikka 1, Grace Lin1, Sorin V. Pislaru 1, and Barry A. Borlaug
Beyond the rhythm: atrial fibrillation, diastolic dysfunction, and heart failure
Riccardo M. Inciardi 1 and Scott D. Solomon
Emery–Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure
Douglas E. Cannie 1,2*, Petros Syrris 1,2, Alexandros Protonotarios1,2, Athanasios Bakalakos1,2, Jean-François Pruny3, Raffaello Ditaranto4,5, Cristina Martinez-Veira6, Jose M. Larra?aga-Moreira6, Kristen Medo7, Francisco José Berm?dez-Jiménez8, Rabah Ben Yaou9, France Leturcq10, Ainhoa Robles Mezcua11,12, Chiara Marini-Bettolo13,14, Eva Cabrera5,15, Chloe Reuter16, Javier Limeres Freire5,12,17, José F. Rodr?guez-Palomares5,12,17, Luisa Mestroni7, Matthew R.G. Taylor7, Victoria N. Parikh16, Euan A. Ashley16, Roberto Barriales-Villa
Emery–Dreifuss muscular dystrophy: a closer look at cardiac complications
Daria Kramarenko and Roddy Walsh
Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis
Piotr Ponikowski 1,2*, Robert J. Mentz 3,4, Adrian F. Hernandez4,5, Javed Butler 6,7, Muhammad Shahzeb Khan8, Dirk J. van Veldhuisen 9, Bernard Roubert10, Nicole Blackman11, Tim Friede 12, Ewa A. Jankowska 1,2†, and Stefan D. Anker
Intravenous iron repletion in heart failure: bridging the gap between symptom relief and hard clinical outcomes
Huda Abu-Own1,2, Ian Webb2, and Darlington O. Okonko
Clinical implementation of partial oral treatment in infective endocarditis: the Danish POETry study
Mia Marie Pries-Heje 1*, Julie Glud Hjulmand1, Ingrid Try Lenz1, Rasmus Bo Hasselbalch 2,3, Jonas Agerlund Povlsen4, Nikolaj Ihlemann5,6, Nana K?ber6, Marlene Lyngborg Tofterup5, Lauge ?stergaard 1, Morten Dalsgaard3, Daniel Faurholt-Jepsen7, Malene Wienberg8, Ulrik Christiansen9, Niels Eske Bruun 10,11,12, Emil Fosb?l1, Claus Moser13,14, Kasper Karmark Iversen 2,3,12†, and Henning Bundgaard
A change in the paradigm of antibiotic management in infective endocarditis: are we ready?
Nuria Fern?ndez-Hidalgo 1,2,3* and Ignacio Ferreira-Gonz?lez
Fulminant myocarditis proven by early biopsy and outcomes
Florent Huang 1,2, Enrico Ammirati3, Maharajah Ponnaiah 4, Santiago Montero 5, Victor Raimbault2, Darryl Abrams6, Guillaume Lebreton 7, Vincent Pellegrino8, Joshua Ihle8, Maurizio Bottiroli3, Romain Persichini9, Marisa Isabel Barrionuevo-S?nchez10, Albert Ariza-Solé10, Pauline Yeung Ng11, Simon Wai Ching Sin12, Raj Ayer13, Hergen Buscher
Endomyocardial biopsy in fulminant myocarditis: need for early and accurate diagnosis to improve the outcome
Heinz-Peter Schultheiss 1* and Felicitas Escher
A 20-year population study of peripartum cardiomyopathy
Alice M. Jackson1, Mark Macartney2, Katriona Brooksbank1, Carolyn Brown3, Dana Dawson 4, Mark Francis5, Alan Japp6, Vera Lennie7, Stephen J. Leslie8, Thomas Martin9, Paul Neary10, Sowmya Venkatasubramanian11, Debra Vickers12, Robin A. Weir13, John J.V. McMurray1, Pardeep S. Jhund 1*, and Mark C. Petrie
Peripartum cardiomyopathy in Europe: new insights from the UK
Charle Viljoen 1,2, Julian Hoevelmann 1,3, and Karen Sliwa
Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy
Mona Allouba 1,2 *†, Roddy Walsh 2,3†, Alaa Afify 1 , Mohammed Hosny 1,4 , Sarah Halawa 1 , Aya Galal 1 , Mariam Fathy1 , Pantazis I. Theotokis 2 , Ahmed Boraey1,4 , Amany Ellithy1 , Rachel Buchan 2,5 , Risha Govind 2,5,6,7 , Nicola Whiffin 2,5,8 , Shehab Anwer 1 , Ahmed ElGuindy 1 , James S. Ware 2,5,9‡ , Paul J.R. Barton 2,5,9‡ , Magdi Yacoub 1,2,10 *‡ , and Yasmine Aguib
The moral and practical urgency of increasing diversity in genomics
Jodie Ingles 1,2,3 * and Daniel G. MacArthur
Prognostic value of intravascular ultrasound early after heart transplantation
Satish Arora 1,2*, Frederik M. Zimmermann3,4, Ole Geir Solberg1, Kari Nytr?en1, Lars Aaberge1, Kozo Okada3, Jung-Min Ahn3,5, Yasuhiro Honda 3, Kiran K. Khush3, Oscar Angeras6, Kristjan Karason6, Lars Gullestad1,2†, and William F. Fearon
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial
Ambarish Pandey 1,2*, Ahmed A. Kolkailah 1,2, Francesco Cosentino 3, Christopher P. Cannon 4, Robert C. Frederich 5, David Z. I. Cherney 6, Samuel Dagogo-Jack 7, Richard E. Pratley 8, Nilo B. Cater 9, Ira Gantz10, James P. Mancuso5, and Darren K. McGuire
Takotsubo syndrome or Takotsubo-like contractile dysfunction?
Liam S. Couch * and Adrian P. Banning
Revisiting the Kv1.5 knockout model: insights and implications for Takotsubo syndrome research
Feng Dong1, Hamayak Sisakian2, and Vahagn Ohanyan
Left atrial pressure-assisted acute heart failure management in the cardiac intensive care unit: a proof-of-concept
Attilio Restivo 1,2, Donato Antonio Paglianiti 1,2, and Domenico D’Amario 3*
Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)
